Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | CTRC | Q99895 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046166 | 0.89 | CALM1 (0.58) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL3821433 | 0.79 | HTR2A (0.56) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL7860817 | 0.79 | L3MBTL1 (0.46) | HSD17B10 | |
| SCHEMBL31167415 | 0.78 | TP53 (0.48) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL11843990 | 0.78 | TP53 (0.48) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL1704793 | 0.77 | CALM1 (0.44) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL1204710 | 0.77 | CALM1 (0.44) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL3917918 | 0.77 | CALM1 (0.44) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL9063880 | 0.77 | IDH1 (0.46) | CALM1BCL2BCL2L1CTRCALOX5 | |
| SCHEMBL29713477 | 0.77 | BCL2 (0.57) | CALM1BCL2BCL2L1ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241595-B2 | Preparation of antiproliferative agent; obtain chemical intermediates, insert into reaction mixture, heat, remove protective groups, recover antiproliferative agent | SANOFI-AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-6610299-B1 | Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-26 | — | — | US | disclosed |
| US-20030064482-A1 | Preparation of antiproliferative agent; obtain chemical intermediates, insert into reaction mixture, heat, remove protective groups, recover antiproliferative agent | HOECHST AKTIENGESELLSCHAFT | 2003-04-03 | — | — | US | disclosed |
| US-6475486-B1 | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-0423747-B1 | Glycosyl-etoposide prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates | BEHRINGWERKE AG (DE) | 1998-07-22 | — | — | EP | disclosed |
| EP-0423747-A2 | Glycosyl-etoposide prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-04-24 | — | — | EP | disclosed |